Treatment of Advanced or Recurrent Cervical Cancer with Cisplatin or Cisplatin Containing Regimens: A Cost Effective Analysis

Geisler, John P.; Swathirajan, Jayanth; Wood, Katherine L.; Manahan, Kelly J.

doi:10.7150/jca.4807

International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

open access Global reach, higher impact

Full Text | PDF

J Cancer 2012; 3:454-458. doi:10.7150/jca.4807 This volume Cite

Research Paper

Treatment of Advanced or Recurrent Cervical Cancer with Cisplatin or Cisplatin Containing Regimens: A Cost Effective Analysis

John P. Geisler^✉, Jayanth Swathirajan, Katherine L. Wood, Kelly J. Manahan

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.

Citation:

Geisler JP, Swathirajan J, Wood KL, Manahan KJ. Treatment of Advanced or Recurrent Cervical Cancer with Cisplatin or Cisplatin Containing Regimens: A Cost Effective Analysis. J Cancer 2012; 3:454-458. doi:10.7150/jca.4807. https://www.jcancer.org/v03p0454.htm

Other styles

Abstract

Background: Trials have demonstrated improvements in survival with adding paclitaxel (P) or topotecan (T) to cisplatin (C) for the treatment of advanced cervical cancer. We sought to evaluate the cost effectiveness of these regimens.

Methods: A decision model was developed based on Gynecologic Oncology Group (GOG) protocols 169 and 179. Arm 1 is 6 cycles of cisplatin. Arm 2 is 6 cycles of CP while arm 3 is 6 cycles of CT. Parameters include overall survival (OS), cost and complications. Sensitivity analyses were performed.

Results: The incremental cost-effectiveness ratio (ICER) for C versus CP is $13,654/quality-adjusted life-year (QALY) gained. For CT compared to C, the ICER is $152,327/QALY. When compared simultaneously, CT is dominated. At a willingness to pay (WTP) threshold of $50,000/QALY, C is the preferred option but CP is acceptable. Sensitivity analyses suggest that CT would become the preferred option if it was to improve OS to 24 months (compared to 9.4 months).

Conclusions: In this model, CP is an acceptable alternative to cisplatin for the treatment of these patients with an increase in cost of only $13,654/QALY. The addition of topotecan did not increase survival enough to justify the increased cost.

Keywords: cervical cancer, chemotherapy, cisplatin, paclitaxel, topotecan.

Citation styles

APA

Geisler, J.P., Swathirajan, J., Wood, K.L., Manahan, K.J. (2012). Treatment of Advanced or Recurrent Cervical Cancer with Cisplatin or Cisplatin Containing Regimens: A Cost Effective Analysis. Journal of Cancer, 3, 454-458. https://doi.org/10.7150/jca.4807.

ACS

Geisler, J.P.; Swathirajan, J.; Wood, K.L.; Manahan, K.J. Treatment of Advanced or Recurrent Cervical Cancer with Cisplatin or Cisplatin Containing Regimens: A Cost Effective Analysis. J. Cancer 2012, 3, 454-458. DOI: 10.7150/jca.4807.

NLM

CSE

Geisler JP, Swathirajan J, Wood KL, Manahan KJ. 2012. Treatment of Advanced or Recurrent Cervical Cancer with Cisplatin or Cisplatin Containing Regimens: A Cost Effective Analysis. J Cancer. 3:454-458.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.